Amgen, AstraZeneca, GSK, Janssen, Eli Lilly, Roche and diagnostic company ThermoFisher Scientific
Access to genomic testing
Canada’s health systems can’t afford to fall behind.
Challenge: Canada isn’t making the grade when it comes to genomic testing—and people living with cancer deserve better. Improving our readiness for genomic testing has the potential to be a game changer, not just for cancer patients, but for the entire health system.
Approach: To raise awareness and drive change, I led the development of a bilingual, integrated campaign that reinforced the findings of The State of Readiness Progress Report by lead researcher Don Husereau. The report revealed that five major provinces—British Columbia, Alberta, Ontario, Quebec, and Nova Scotia—are lagging in both infrastructure and operational readiness to adopt genome-based testing.
Objective: Our campaign called for equitable access to genome-based testing, ensuring that no matter where a patient lives or receives treatment, they could benefit from this rapidly evolving innovation. The ultimate goal was to highlight the life-changing potential of genomic testing: enabling more informed treatments and, in turn, delivering better health outcomes.
Result: By combining research-driven insights with compelling storytelling, the campaign amplified the urgency of the issue and mobilized stakeholders around the shared vision of making equitable genomic testing a reality across Canada.
related portfolio items
							
						
							
						
							
						
							
						
							
						
							
						
							
						
							
						
							
						
							
						
